Get the Stockscreener App
136.94
3.26%
4.32
After Hours:
136.94
Krystal Biotech Inc stock is traded at $136.94, with a volume of 265.79K.
It is up +3.26% in the last 24 hours and down -1.81% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$132.62
Open:
$134.23
24h Volume:
265.79K
Relative Volume:
0.80
Market Cap:
$3.64B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
45.80
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+8.72%
1M Performance:
-1.81%
6M Performance:
-26.08%
1Y Performance:
-17.35%
1-Day Range:
$134.23
$136.95
1-Week Range:
$124.00
$136.95
52-Week Range:
$122.80
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
136.94 | 3.64B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? - Yahoo Finance
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
H.C. Wainwright maintains Krystal Biotech stock Buy rating at ASCO 2025 - Investing.com Nigeria
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
How To Trade (KRYS) - news.stocktradersdaily.com
Krystal Biotech Reports Promising Results for KB707 Trial - TipRanks
Implied Volatility Surging for Krystal Biotech Stock Options - TradingView
Krystal Biotech Enters Oversold Territory (KRYS) - Nasdaq
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Lazard Asset Management LLC Sells 922 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
D. E. Shaw & Co. Inc. Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Why We're Not Concerned Yet About Krystal Biotech, Inc.'s (NASDAQ:KRYS) 26% Share Price Plunge - simplywall.st
Bank of America Corp DE Has $11.88 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech stock hits 52-week low at $127.33 By Investing.com - Investing.com South Africa
Krystal Biotech Holds Annual Stockholders Meeting - MSN
Krystal Biotech stock hits 52-week low at $127.33 - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Cut by BNP Paribas Financial Markets - Defense World
Citigroup Lowers Krystal Biotech (NASDAQ:KRYS) Price Target to $155.00 - Defense World
Krystal Biotech (KRYS) Price Target Lowered by Citigroup | KRYS Stock News - GuruFocus
The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts - Benzinga
Krystal Biotech (KRYS) Sees Price Target Cut Amid Sales Forecast Adjustment | KRYS Stock News - GuruFocus
H.C. Wainwright maintains Buy on Krystal Biotech shares By Investing.com - Investing.com Nigeria
Transcript : Krystal Biotech, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11 - marketscreener.com
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat
Krystal Biotech's (NASDAQ:KRYS) Solid Earnings Have Been Accounted For Conservatively - Yahoo Finance
Krystal Biotech Expands Gene Therapy Platform - TipRanks
How the (KRYS) price action is used to our Advantage - news.stocktradersdaily.com
FY2025 EPS Estimates for Krystal Biotech Lowered by Analyst - Defense World
Cantor Fitzgerald Predicts Krystal Biotech FY2025 Earnings - Defense World
Q4 EPS Estimates for Krystal Biotech Lifted by HC Wainwright - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Krystal Biotech, Inc. (KRYS): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
H.C. Wainwright maintains Buy on Krystal Biotech shares - Investing.com Australia
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates - MSN
Krystal Biotech "insulated" by domestic manufacturingPittsburgh Business Times - The Business Journals
Krystal Biotech (KRYS) Price Target Lowered by Guggenheim | KRYS Stock News - GuruFocus
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target - GuruFocus
Krystal Biotech (KRYS) Faces Hurdles After Lowered Price Target | KRYS Stock News - GuruFocus
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - The Manila Times
Krystal Biotech (KRYS) Maintains Buy Rating and Price Target | KRYS Stock News - GuruFocus
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Rec - GuruFocus
Earnings call transcript: Krystal Biotech misses Q1 2025 EPS forecast, stock drops 14% - Investing.com Nigeria
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q1 2025 Results - TipRanks
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
Krystal Biotech outlines 2025 global launch strategy with $88.2M Q1 VYJUVEK revenue - MSN
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):